The developed system encapsulated three different agents: adriamycin, as a cancer chemotherapeutic, as well as MVP-siRNA and BCL2-siRNA to inhibit the major vault protein (MVP) and the B-cell lymphoma-2 (BCL2) gene which are responsible for the multidrug resistance exhibited by the specific cells. This evidence concerns the gene MVP and cancer.